The tweet was deleted by the author.
But we saved everything 🙂.
Allogene Therapeutics is integrating investigational minimal residual disease (MRD) testing technology with its off-the-shelf CAR T cell therapy in the ALPHA3 trial targeting large B-cell lymphoma (LBCL).
The company aims to intervene earlier in the treatment pathway for LBCL, where one in three patients experience cancer recurrence after first-line therapy. This trial is designed to potentially improve cure rates among these patients.
View post on X Loading...